Adaptimmune Therapeutics (ADAP) Rating Lowered to Sell at BidaskClub

Adaptimmune Therapeutics (NASDAQ:ADAP) was downgraded by BidaskClub from a “hold” rating to a “sell” rating in a research note issued to investors on Wednesday.

A number of other equities analysts have also commented on ADAP. TheStreet upgraded shares of Adaptimmune Therapeutics from a “d” rating to a “c” rating in a report on Thursday, November 2nd. Zacks Investment Research lowered shares of Adaptimmune Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, November 10th. ValuEngine lowered shares of Adaptimmune Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, December 1st. SunTrust Banks reiterated a “buy” rating and issued a $10.00 price objective on shares of Adaptimmune Therapeutics in a report on Thursday, October 12th. Finally, Leerink Swann reiterated an “outperform” rating and issued a $15.00 price objective on shares of Adaptimmune Therapeutics in a report on Friday, September 8th. Two analysts have rated the stock with a sell rating, two have given a hold rating and three have given a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus price target of $11.58.

Adaptimmune Therapeutics (NASDAQ:ADAP) opened at $7.06 on Wednesday. Adaptimmune Therapeutics has a 1-year low of $3.85 and a 1-year high of $9.29.

Several institutional investors have recently modified their holdings of the company. Matrix Capital Management Company LP acquired a new stake in shares of Adaptimmune Therapeutics in the 2nd quarter valued at about $39,027,000. Baillie Gifford & Co. raised its stake in Adaptimmune Therapeutics by 4.2% during the third quarter. Baillie Gifford & Co. now owns 1,379,304 shares of the biotechnology company’s stock worth $11,297,000 after acquiring an additional 55,996 shares during the period. Artal Group S.A. raised its stake in Adaptimmune Therapeutics by 66.7% during the third quarter. Artal Group S.A. now owns 500,000 shares of the biotechnology company’s stock worth $4,095,000 after acquiring an additional 200,000 shares during the period. Graticule Asia Macro Advisors LLC acquired a new stake in Adaptimmune Therapeutics during the third quarter worth about $3,242,000. Finally, Rathbone Brothers plc raised its stake in Adaptimmune Therapeutics by 60.1% during the third quarter. Rathbone Brothers plc now owns 321,050 shares of the biotechnology company’s stock worth $2,629,000 after acquiring an additional 120,525 shares during the period. Institutional investors and hedge funds own 54.24% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This report was first reported by Community Financial News and is the property of of Community Financial News. If you are accessing this report on another website, it was copied illegally and reposted in violation of US & international trademark & copyright legislation. The original version of this report can be accessed at https://www.com-unik.info/2017/12/22/adaptimmune-therapeutics-adap-rating-lowered-to-sell-at-bidaskclub.html.

About Adaptimmune Therapeutics

Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform. The Company has developed a platform that enables it to identify cancer targets, find and genetically engineer TCR, and produce TCR therapeutic candidates for administration to patients.

What are top analysts saying about Adaptimmune Therapeutics? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Adaptimmune Therapeutics and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit